Last reviewed · How we verify

AGEE cream

University of Nebraska · FDA-approved active Small molecule Quality 2/100

AGEE cream, developed by the University of Nebraska, is a marketed topical treatment with a key composition patent expiring in 2028. The drug's primary strength lies in its unique mechanism of action, which differentiates it from existing treatments. The primary risk is the potential for increased competition once the key patent expires in 2028.

At a glance

Generic nameAGEE cream
Also known ascreatine ethyl ester based topical
SponsorUniversity of Nebraska
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results